Table: “Drugmakers Mine DNA Troves For Research: Selected Genetic Databases and Their Industry Partners”, in Wall Street Journal, July 24, 2019. p. B1.
23andMe (8 million individuals): Genentech, GlaxoSmithKline.
deCODE Genetics (owned by Amgen) (1.6 million individuals): Amgen.
UK Biobank (0.5 million individuals): AbbVie, Alnylam, AstraZeneca, Biogen, Bristol-Myers Squibb, GlaxoSmithKline, Pfizer, Regeneron, Takeda Pharmaceuticals.
Geisinger (part of Roche) (0.25 million individuals): Regeneron.
FinnGen (0.146 million individuals): AbbVie, AstraZeneca, Biogen, Celgene, Genetech, GlaxoSmithKline, Merck, Pfizer, Sanofi.
Mayo Clinic (0.1 million individuals (target)): Regeneron.
Source: the companies.